Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.52M P/E - EPS this Y 49.20% Ern Qtrly Grth -
Income -24.55M Forward P/E -3.00 EPS next Y -6.30% 50D Avg Chg -10.00%
Sales 10M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 3.28 EPS next 5Y - 52W High Chg -46.00%
Recommedations 2.00 Quick Ratio 1.87 Shares Outstanding 84.82M 52W Low Chg 24.00%
Insider Own 1.96% ROA -31.13% Shares Float 83.16M Beta 1.27
Inst Own 8.67% ROE -84.31% Shares Shorted/Prior 554.11K/1.79M Price 1.02
Gross Margin 99.00% Profit Margin -245.47% Avg. Volume 332,252 Target Price 6.00
Oper. Margin -246.98% Earnings Date Mar 29 Volume 61,209 Change 0.00%
About Dare Bioscience, Inc.

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Dare Bioscience, Inc. News
07:00 AM Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
03/01/23 Daré Bioscience to Present at the 35th Annual Roth Conference
02/22/23 Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
02/01/23 Daré Bioscience to Participate in Three February Conferences
01/26/23 Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
01/21/23 Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 49% if they invested five years ago
01/09/23 All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
01/09/23 Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
12/12/22 Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
12/11/22 We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
11/15/22 Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
11/15/22 Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
11/14/22 Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
11/10/22 Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
11/10/22 Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
11/08/22 Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
11/03/22 Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
11/01/22 Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
10/17/22 Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
10/10/22 Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
DARE Chatroom

User Image RiverBottomBluze Posted - 30 minutes ago

$DARE Now begins the wise sage infestation, pundits with no skin in the game, offering their expert knowledge and opinions. Short DARE and post your short prior to claiming your gains (or losses) if you are so absolutely sure that you know what is going to happen next week when the report is released. IF this DARE is the garbage company you claim it is, it should be a slam dunk. Care to back up your words??? I am willing to bet all we hear is crickets...

User Image RayRaySamuelz_XVII Posted - 30 minutes ago

$DARE Sabrina told you why Xaciato took so long to get to market. COVID supply chain issues are no joke. Sometimes outside factors are unavoidable. It's how these choppy waters are navigated that separates the great ones from all the rest. These weren't protected forward looking statements she gave. This was on the record, public commentary on past events. Believe her or don't. Sue her if you don't. IDGAF, I'm here to make money.

User Image MEK_melter Posted - 39 minutes ago

$DARE fyi, Ray is the man IMO

User Image Thecannonbull Posted - 50 minutes ago

$DARE What Im really excited to see is the cash burn and cash on hand. Its going to be awesome. I expect "so we are spending like drunken sailors and we dont have any cash left" will there be a carrot? Will there be something to lube to obvious need for capital? Will they say hey we are about to fuck you so hard over a barrel you'll start using pronouns like our staff but first look a shiny new pipeline trial for some trash no one will ever buy? Fun times ahead, still a shit company with trash management.

User Image Stress3 Posted - 52 minutes ago

$DARE but what the cheerleaders aren’t saying is the Ovaprene study doesn’t have a start date and it’s a year long study. So that’s a year from an unknown start date and then approval time. That puts it years away from helping shareholders make $. It’s not a slam dunk thing happening. Like everything involving Dare, it’s years and years away. Remember last year, Sabrina said that third trial of Ovaprene was starting then too and Xaciato was being released by fourth quarter 2022. It’s March, 2023 and neither of those things has happened.

User Image RayRaySamuelz_XVII Posted - 1 hour ago

$DARE Bid slammers losing their grip. Sabrina = GOAT

User Image RayRaySamuelz_XVII Posted - 1 hour ago

$DARE Remember, Ovaprene Phase 3 is effectively paid for. So important for a company of this size. And with the recent FDA nod, Phase 3 coming soon. This is huge news considering the hidden safety failures of the IUD and Nuvaring. FDA was walking on eggshells, but still said OK. Ovaprene is the real deal my friends. Hormone free, and only once a month? Yes, please. The sprint is coming.

User Image Stress3 Posted - 1 hour ago

$DARE oh wow. Look at it fly! I’m being sarcastic. The market is up and it barely affects Daré. Why you ask? Well, nothing has changed. No products. No news. No third trials. Cheerleading isn’t enough. Doesn’t matter what the price target is, or the buy consensus. Those both have been high for years. Results matter. There is nothing going on to get results. Sorry. I wish I were wrong, but per usual, I’m not. Cheerleaders only need to be right once, yet it’s all talk. Changes need to be made with this company to get the results you want to happen. That’s the facts.

User Image Champ79 Posted - 2 hours ago

$DARE I believe we are about to see some good moves until the quarterly meeting next week! Loading...

User Image Explorer2234 Posted - 3 hours ago

$DARE Q2 will sure be interesting!!

User Image shankarhoonmashankar Posted - 3 hours ago

@Thecannonbull Short it then, I $DARE i $DARE $DARE you!

User Image Thecannonbull Posted - 3 hours ago

$DARE What will earnings show? Zero revenue? Zero sales? Zero hope?

User Image BiotechJedi1728 Posted - 4 hours ago

$DARE It’s coming. https://twitter.com/darebioscience/status/1638874039472234498?s=12&t=jRSFrsX_uru4O6gf5r0vqA

User Image Quantisnow Posted - 4 hours ago

$DARE 📰 Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 https://quantisnow.com/i/4238815?utm_source=stocktwits 45 seconds delayed.

User Image Stock_Titan Posted - 4 hours ago

$DARE Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 https://www.stocktitan.net/news/DARE/dare-bioscience-to-host-full-year-2022-financial-results-and-company-c1a8bb4knsnd.html

User Image Easternbikes5 Posted - 5 hours ago


User Image Ratata0912 Posted - 5 hours ago


User Image risenhoover Posted - 6 hours ago

$DARE DARE / Dare Bioscience Inc Price Target Updated https://fintel.io/sfo/us/dare?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image Stress3 Posted - 9 hours ago

$DARE Disgusting. Congrats you can count. Too bad you have nothing of significance to say. I do have something to say. Notice you aren’t right once because here we are, hovering around $1, still no revenue or products. Just wishful thinking on your part. How’s that working? I guess not we’ll if being so wrong bothers you so much when people point out their concerns. Grow up.

User Image ChartMill Posted - 11 hours ago

$DARE was analyzed by 12 analysts. The buy consensus is at 82%. So analysts seem to be very confident about $DARE. https://www.chartmill.com/stock/quote/DARE/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=DARE&utm_campaign=social_tracking

User Image BiotechJedi1728 Posted - 15 hours ago

$AGRX $DARE $OGN Think it is funny…now we see profits women’s health. Yes. You can make money here. All completely undervalued and trading a third of where they should be.

User Image Punted Posted - 16 hours ago

$DARE imagine having all the accomplishments and not being able to get a product to the same people you say you care about! Sabrina Martucci Johnson - President and CEO Ms. Johnson is a life sciences executive committed to advancing improvements in women’s healthcare. Ms. Johnson has a Masters of International Management degree with honors from the American Graduate School of International Management (Thunderbird), a MSc in Biochemical Engineering from the University of London, University College London and a BSc in Biomedical Engineering from Tulane University, where she graduated magna cum laude.

User Image Delthefunkyhomosapian Posted - 17 hours ago

$DARE I logged out and saw Punted posted 7 times today. Really makes you wonder about his intentions here. His alternative account stress3 posted 5 times. This website is truly terrible.

User Image Punted Posted - 17 hours ago

$DARE poor bulls. troubled company organon in zero hurry to bring product to market. oveprene is shelved for time being sildenafil - they ”needed” more data so opened a new study. nothing close to the boat. but hey some say this is a really well run company. lol not really

User Image BiotechJedi1728 Posted - 18 hours ago

$DARE AH games as usual. SMH.

User Image Stress3 Posted - 18 hours ago

$DARE and the current thing they could get out, they aren’t. Xaciato was fast tracked in 2021. Date doesn’t use the ones they have available, so what makes you think the stuff in the works will even be ready anytime soon. It won’t. Years away. The company may not even make it to releasing anything. Some are saying a sale is in the works. That explains why nothing else is happening, no release of Xaciato , no third trial trial participants picked, etc. Instead of just admitting the future is unknown, you stick to how great Dare is and how it’s a money making opportunity. In ten years, I won’t need Dare to make $. I need it now. Have been waiting four years. Four more still won’t make a difference. And Dare is uninterested in getting products out there. I think they want that stock price low. I think it’s about selling the company, along with the future maybe pipeline.

User Image Stress3 Posted - 18 hours ago

$DARE any “mind blowing potential” is years away. Years and years away.

User Image BiotechJedi1728 Posted - 20 hours ago

$DARE Thought Fed easing would gently move this today but Powell was too hawkish at his presser compared to the PR. Other stocks moving up, but as always expect a delayed response here. Plus with ER and announcements coming, ppl content to wait a little seems. No matter. Good buying point for me. Getting some more powder lined up for next round. Try to get in before blast off 🚀

User Image RayRaySamuelz_XVII Posted - 21 hours ago

$DARE Trolls ignore the astonishing progression and mind-blowing potential. Their loss. Way more money to be made licking winners as opposed to the pennies per post hedge funds flip their way.

User Image NotFinancialAdvice007 Posted - 22 hours ago

$DARE dumb pick here

Analyst Ratings
HC Wainwright & Co. Buy Dec 13, 22
JonesTrading Buy Dec 1, 22
HC Wainwright & Co. Buy Apr 1, 22
Roth Capital Buy Jun 30, 21
HC Wainwright & Co. Buy Dec 18, 20
Brookline Capital Buy Apr 28, 20
Maxim Group Buy Aug 17, 18